5[1]Xu L, Villain M, Galin FS, et al. Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells. Cell Immunol, 2001, 208(2): 107-114.
6[3]Lennon VA. Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs. J Exp Med,1975,141:1365.
7[5]Howard JF. Adverse drug effects on neuromuscular transmission. Semin Neurol,1990,10(1):89-102.
8[6]Christadoss P,Poussin M,Deng C. Animal models of myasthenia gravis[J]. Clin Immunol, 2000,94(2):75-87.
9Feferman T,Im SH,Fuchs S,et al.Breakage of tolerance to hidden cyto plasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis[J].Neuroimmunol,2003,140(1-2):153-158.
10Nieto PI,Roblel PPJ,Pajulo CM,et al.Prognostic factors for myasthenia gravis treated by thymectomy:review of 61 cases[J].Ann Thorac surg,1999,67(6):1568-1571.
5Wittbrodt ET. Drugs and myasthenia gravis. An update[J]. J Arch Intern Med, 1997, 157(4): 399-408. Van.
6Berkel MA, Twilla JD, England BS. Emergency department of a Myasthenia Gravis patient with community- acquired pneumonia: does initial antibiotic choice lead to cure or crisis? [J]. J Emerg Med, 2016, 50(2): 281-285.
8US Food and Drug Administration. FDA Safety Information: Risk of fluoroquinolone-associated Myasthenia Gravis Exacerbation February 2011 Label Changes for Fluoroquinolones [EB/OL]. (2011-03-15)[2016-10-11 ]. http: //www.fda.gov/safety/medwatch/safetyinformation/ ucm247115.htm.
9Cadisch R, Streit E, Hartmann K. Exacerbation of pseudo- paralytic myasthenia gravis following azithromycin (Zithromax)[J]. Schweiz Med wochenschr, 1996, 126(8): 308- 310.
10Pradhan S, Pardasani V, Ramteke K. Azithromycin-induced myasthenic crisis: reversibility with calcium gluconate[J]. Neurol India, 2009, 57(3): 352-353.
